Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PFE 
Pfizer Inc (PFE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: PFE (1-star) is a SELL. SELL since 3 days. Simulated Profits (-5.33%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
25 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $28.86
1 Year Target Price $28.86
| 7 | Strong Buy |
| 2 | Buy |
| 15 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.55% | Avg. Invested days 31 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 135.88B USD | Price to earnings Ratio 12.65 | 1Y Target Price 28.86 |
Price to earnings Ratio 12.65 | 1Y Target Price 28.86 | ||
Volume (30-day avg) 25 | Beta 0.46 | 52 Weeks Range 20.18 - 28.43 | Updated Date 09/17/2025 |
52 Weeks Range 20.18 - 28.43 | Updated Date 09/17/2025 | ||
Dividends yield (FY) 7.09% | Basic EPS (TTM) 1.89 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 16.84% | Operating Margin (TTM) 28.68% |
Management Effectiveness
Return on Assets (TTM) 5.25% | Return on Equity (TTM) 12.17% |
Valuation
Trailing PE 12.65 | Forward PE 7.66 | Enterprise Value 183561656950 | Price to Sales(TTM) 2.13 |
Enterprise Value 183561656950 | Price to Sales(TTM) 2.13 | ||
Enterprise Value to Revenue 2.88 | Enterprise Value to EBITDA 9.11 | Shares Outstanding 5685550080 | Shares Floating 5675885064 |
Shares Outstanding 5685550080 | Shares Floating 5675885064 | ||
Percent Insiders 0.07 | Percent Institutions 67.09 |
Upturn AI SWOT
Pfizer Inc
Company Overview
History and Background
Pfizer Inc. was founded in 1849 by Charles Pfizer and Charles Erhart in New York City. Initially a fine-chemicals business, Pfizer evolved into a global pharmaceutical giant through innovation, strategic acquisitions, and a focus on developing and marketing prescription medicines and vaccines.
Core Business Areas
- Biopharma: Focuses on discovering, developing, manufacturing, marketing, sales and commercialization of innovative medicines and vaccines. This segment generates the majority of Pfizer's revenue. Key therapeutic areas include oncology, inflammation & immunology, internal medicine, vaccines, and rare diseases.
Leadership and Structure
Pfizer is led by CEO Albert Bourla. The company operates under a divisional structure, with specialized units focused on specific therapeutic areas and geographic regions.
Top Products and Market Share
Key Offerings
- Comirnaty (COVID-19 Vaccine): A messenger RNA (mRNA) vaccine developed in partnership with BioNTech. It holds a significant market share, initially dominating the market, but facing increasing competition from Moderna and other vaccines. Revenue dramatically decreased after 2022 due to decreased pandemic effects. Competitors are Moderna and Novavax.
- Prevnar 13/20 (Pneumococcal Vaccine): A vaccine to protect against pneumococcal disease. Competitors include Merck's Pneumovax 23.
- Eliquis (Anticoagulant): An anticoagulant used to prevent blood clots. Market share and revenue details are significant. Competitors include Xarelto (Bayer/Johnson & Johnson) and other DOACs.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, stringent regulatory oversight, and patent protection. Key trends include personalized medicine, gene therapy, and biologics. The industry is driven by aging populations, increasing healthcare spending, and technological advancements.
Positioning
Pfizer is a leading player in the pharmaceutical industry, with a strong portfolio of established drugs and a robust pipeline of new products. Its competitive advantages include its global scale, research capabilities, and established brand reputation.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated at over $1 trillion. Pfizer, with its diverse portfolio, aims to capture a significant portion of this market, particularly in areas like oncology, vaccines, and anti-inflammatory drugs. Pfizer's diversification and investment in innovative therapies position it to compete for substantial market share.
Upturn SWOT Analysis
Strengths
- Strong Brand Recognition
- Extensive Global Presence
- Diverse Product Portfolio
- Robust R&D Pipeline
- Proven Track Record of Successful Acquisitions
Weaknesses
- Patent Expirations (Loss of Exclusivity)
- Dependence on Key Products
- High Debt Levels
- Exposure to Litigation Risks
Opportunities
- Emerging Markets Growth
- Development of Novel Therapies (e.g., gene therapy)
- Strategic Acquisitions and Partnerships
- Expansion of Vaccine Portfolio
- Increased Healthcare Spending Globally
Threats
- Generic Competition
- Price Controls and Reimbursement Pressures
- Regulatory Changes
- Economic Downturns
- Competition from other Pharma Giants
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- ABBV
- LLY
- NVS
Competitive Landscape
Pfizer faces competition from other large pharmaceutical companies, as well as smaller biotechnology firms. Its advantages include its scale and diverse product portfolio, while disadvantages include its dependence on key products and exposure to generic competition.
Major Acquisitions
Arena Pharmaceuticals
- Year: 2022
- Acquisition Price (USD millions): 6700
- Strategic Rationale: Expanded Pfizer's capabilities in immuno-inflammatory diseases.
Seagen
- Year: 2023
- Acquisition Price (USD millions): 43000
- Strategic Rationale: Accelerate advancement in cancer treatments.
Growth Trajectory and Initiatives
Historical Growth: Pfizer's growth has been driven by both organic development and acquisitions. Revenue has fluctuated depending on patent expirations and the success of new product launches.
Future Projections: Analyst estimates vary depending on market conditions, but future growth is expected to be driven by new product launches and expansion in emerging markets.
Recent Initiatives: Recent initiatives include strategic acquisitions, investments in R&D, and partnerships to develop new therapies.
Summary
Pfizer is a large, established pharmaceutical company with a diverse product portfolio and global presence. While it faces challenges from patent expirations and competition, it also has opportunities for growth through new product launches and strategic acquisitions. The company's financial performance is solid, but its future growth depends on its ability to innovate and adapt to changing market conditions. Pfizer must also look at its debt and find ways to pay it down.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Pfizer Investor Relations
- SEC Filings
- Company Press Releases
- Industry Reports
- Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pfizer Inc
Exchange NYSE | Headquaters New York, NY, United States | ||
IPO Launch date 2012-08-13 | Chairman of the Board & CEO Dr. Albert Bourla D.V.M., Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 81000 | Website https://www.pfizer.com |
Full time employees 81000 | Website https://www.pfizer.com | ||
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.